Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373

Gastroenterology

  • Home
  • Gastroenterology
Headache Relief Shampoo Voted #1 Best New Product in 2019

Dr. D’s Medicated Headache Relief Shampoo is now available. This medicated shampoo will help alleviate headaches simply by soaking it on your head. Finding relief from minor to severe headaches shouldn’t always involve reaching for a bottle of pills. Dr. D is here to give you another option. Our proprietary formula will leave your head feeling better.

BUY NOW! http://headachereliefshampoo.com/product/headache-relief-shampoo/

January 1, 2019 / by / in
Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers
Condition:   MUC17-positive Solid Tumors
Intervention:   Drug: AMG 199
Sponsor:   Amgen
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 15, 2021 / by / in
Management of Symptomatic Gastric Sleeve Stenosis After Laparoscopic Sleeve Gastrectomy
Condition:   Gastric Stenosis
Interventions:   Procedure: Endoscopic pneumatic balloon dilation;   Procedure: Gastric peroral endoscopic myotomy (G-POEM);   Procedure: Roux-en-Y gastric bypass (RYGB)
Sponsor:   Johns Hopkins University
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 11, 2021 / by / in
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
Conditions:   Ovarian Cancer;   Ovarian Neoplasms;   Ovarian Carcinoma;   Endometrial Cancer;   Colorectal Cancer;   Gastric Cancer;   Gastroesophageal Junction Adenocarcinoma;   Gastric Adenocarcinoma;   TNBC – Triple-Negative Breast Cancer;   Triple Negative Breast Cancer;   Cholangiocarcinoma;   Bile Duct Cancer;   Colon Cancer;   Colon Cancer Stage;   Colon Neoplasm;   Colon Adenocarcinoma;   Colon Rectal Cancer;   Colon Cancer Liver Metastasis;   Colorectal Neoplasms;   Colorectal Carcinoma;   Colorectal Adenocarcinoma;   Colorectal Cancer Metastatic;   Colorectal Cancer Stage IV;   Rectum Cancer;   Rectum Neoplasm;   Rectum Carcinoma;   Rectal Cancer;   Rectal Neoplasms;   Rectal Adenocarcinoma;   Rectal Cancer Stage;   Rectal Cancer Metastatic;   Rectal Cancer Stage III;   Esophagus Cancer;   Esophageal Cancer;   Esophageal Neoplasms;   Gastric Cancer Stage;   Breast Cancer;   Breast Neoplasm;   Breast Adenocarcinoma;   Breast Cancer Stage IV;   Breast Cancer Stage;   Breast Cancer Metastatic;   Breast Cancer Invasive;   Triple Negative Breast Neoplasms;   Intrahepatic Cholangiocarcinoma;   Intrahepatic Cholangiocarcinoma Recurrent;   Hilar Cholangiocarcinoma;   Distal Cholangiocarcinoma;   Ovary Cancer;   Ovary Neoplasm;   Ovary Disease;   Ovary Metastasis;   Ovarian Diseases;   Ovarian Cancer Stage;   Ovarian Epithelial Cancer;   Ovarian Adenocarcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Neoplasm Epithelial;   Ovarian Cancer Recurrent;   Endometrial Diseases;   Endometrial Adenocarcinoma;   Endometrial Carcinosarcoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrioid Adenocarcinoma;   Endometrial Neoplasms;   Endometrial Cancer Recurrent;   Endometrioid Tumor;   Fallopian Tube Cancer;   Peritoneal Cancer
Intervention:   Drug: ELU001
Sponsor:   Elucida Oncology
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 10, 2021 / by / in
RegoNivo vs Standard of Care Chemotherapy in AGOC
Condition:   Gastro-Oesophageal Cancer
Interventions:   Drug: Regorafenib;   Biological: Nivolumab;   Drug: Docetaxel;   Drug: Paclitaxel;   Drug: Irinotecan;   Drug: Trifluridine/Tipracil
Sponsors:   Australasian Gastro-Intestinal Trials Group;   Bayer;   Bristol-Myers Squibb;   University of Sydney;   Academic and Community Cancer Research United;   Taiwanese Cooperative Oncology Group;   Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 31, 2021 / by / in
AspireAssist for Palliative Venting Gastrostomy in Malignant Bowel Obstruction Patients
Conditions:   Malignant Small Bowel Obstruction;   Malignant Gastric Outlet Obstruction
Interventions:   Device: AspireAssist device;   Device: Standard decompressive PEG tube;   Other: gastric outlet obstruction scoring system (GOOSS) questionnaire;   Other: Modified Gastroparesis Cardinal Symptom Index (GCSI) questionnaire;   Other: Patient satisfaction and ease of use survey
Sponsor:   Case Comprehensive Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 24, 2021 / by / in
LINX Reflux Management System or Fundoplication Clinical Study in Patients With Hiatal Hernia >3 cm
Conditions:   Hiatal Hernia Large;   Gastro Esophageal Reflux;   Hiatal Hernia;   Hiatal Hernia, Paraesophageal;   Reflux, Gastroesophageal;   Reflux Acid
Interventions:   Device: LINX Reflux Management System;   Procedure: Fundoplication
Sponsor:   Foregut Research Foundation
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 21, 2021 / by / in
Phase I Study of IGM-8444 as a Single Agent and in Combination in Subjects With Relapsed and/or Refractory Solid Cancers
Conditions:   Solid Tumor;   Colorectal Cancer;   Gastric Cancer;   Non Hodgkin Lymphoma;   Non-Small Cell Lung Cancer;   Sarcoma;   Chondrosarcoma;   Small Lymphocytic Lymphoma;   Chronic Lymphocytic Leukemia
Interventions:   Drug: IGM-8444;   Drug: FOLFIRI;   Drug: Bevacizumab (and approved biosimilars);   Drug: Birinapant;   Drug: Venetoclax
Sponsor:   IGM Biosciences, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 21, 2021 / by / in
Study of TT-00420 Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
Conditions:   Advanced Solid Tumor;   Cholangiocarcinoma;   HER2-negative Breast Cancer;   Triple Negative Breast Cancer;   Bladder Cancer;   Small-cell Lung Cancer;   Prostate Cancer;   Thyroid Cancer;   Sarcoma;   Gastric Cancer;   Gallbladder Cancer
Interventions:   Drug: TT-00420;   Combination Product: Nab-Paclitaxel
Sponsor:   TransThera Biosciences Co., Ltd
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 10, 2021 / by / in
Domperidone Expanded Access Treatment Program
Condition:   Gastroparesis
Intervention:   Drug: Domperidone Oral Product
Sponsor:   Aurora Health Care
Available

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 10, 2021 / by / in
Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma
Conditions:   Gastric Cancer;   Hepatocellular Carcinoma
Interventions:   Drug: Telatinib;   Drug: Keytruda
Sponsors:   Andrew Hendifar, MD;   EOC Pharma
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 5, 2021 / by / in